Pharmaceutical Technology on MSN
Kyowa Kirin secures FDA approval for Crysvita dosing update
Following the update, healthcare providers can increase both the dose and frequency of Crysvita for XLH patients after treatment.
1d
Ipsen unveils corabotase, a first-in-class recombinant neuroinhibitor, RNI™, at the SCALE Symposium
Corabotase is the first investigational molecule in a newly designated class of recombinant neuroinhibitors, RNITM, as recognized by the WHO and ...
InVitria, a global leader in chemically defined, animal-origin-free recombinant proteins for advanced therapy manufacturing, announced its participation in the American Society of Gene and Cell ...
MedPage Today on MSN
What a U.S. Study Found About the Shingles Vaccine and Dementia
Analysis assessed dementia risk with the current two-dose shot ...
Corabotase is the first investigational molecule in a newly designated class of recombinant neuroinhibitors, RNITM, as recognized by the WHO and USAN Phase II data in glabellar (frown) lines to be fea ...
The recombinant cell culture supplements market is set to grow due to rising biologics demand and advances in gene therapy.
Advanced materials science sits at the intersection of biology, chemistry, and engineering. Recombinant spider silk is ...
Q1 2026 Earnings Call May 13, 2026 5:00 PM EDTCompany ParticipantsPing Rawson - Chief Financial OfficerJoseph Hazelton ...
Genetically engineered cultured host cells containing recombinant nucleic acids useful for gene therapy are patent-eligible for being ...
Recombinant adeno-associated virus (AAV) vectors are predominantly nonintegrating, but rare genomic integration events have been associated with oncogenesis in neonatal murine models. Here we ...
A new study has found that U.S. adults over the age of 65 who received both doses of the recombinant zoster shingles vaccine (Shingrix) had a lower rate of dementia than others in the same age group.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results